|
COPYRIGHT 2001 PR Newswire Association LLC
SAN DIEGO, May 31 /PRNewswire/ --
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced today that its wholly owned subsidiary, Amylin Europe, Ltd has submitted Marketing Authorization Applications for SYMLIN(TM) (pramlintide acetate) to the European Agency for the Evaluation of Medicinal Products (EMEA) under the centralized European Community procedure for the authorization of medicinal products. A medicinal product approved using the centralized procedure can be put on the market in all fifteen Member States of the...
Read the full article for free courtesy of your local library.
| 
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
